Symbols

PEN

Penumbra·NYSE

--(--)

PEN fundamentals

PEN Q3 2025 Earnings

Penumbra (PEN) released its earnings on Nov 5, 2025: revenue was 354.69M (YoY +17.82%), beat estimates; EPS was 0.97 (YoY +14.12%), beat estimates.

Revenue / YoY

354.69M

+17.82%

EPS / YoY

0.97

+14.12%

Report date

Nov 5, 2025

PEN Earnings Call Summary for Q3,2025

Revenue Growth: Q3 2025 revenue up 17.8% YoY to $354.7M, driven by 34% VTE growth and 29.2% embolization/access expansion.
CAVT Innovation: FDA clears Lightning Bolt 16 and Flash 3.0; STORM-PE trial validates CAVT superiority, spurring hospital protocol updates.
Margin Expansion: Gross margin 67.8% (up 130bps YoY); targeting >70% by 2026. Operating income $48.8M (13.8% of revenue).
Guidance Update: 2025 revenue raised to $1.375-$1.380B; U.S. thrombectomy growth 20-21%.
Pipeline Momentum: Thunderbolt FDA review active; Flash 3.0 enhances case efficiency, Ruby XL stabilizes production.

Earnings

EPS

Revenue

Revenue & Expenses

PEN has released its 2025 Q4 earnings report, with revenue of 385.38M, reflecting a YoY change of 22.14%, and net profit of 47.34M, showing a YoY change of 40.55%. The Sankey diagram below clearly presents PEN's revenue sources and cost distribution.

Key Indicators

Penumbra (PEN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Penumbra (PEN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Penumbra (PEN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Penumbra (PEN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown